Table 3.

Meta-analyses of recent randomized controlled trials on stem cells use for acute myocardial infarction and heart failure.

Author Year of publication [Reference number]	Patient diagnosis, Route of stem cells delivery	Main clinical findings	Number of trials, Number of patients	Follow-up time (months)
Zhang et al. 2008 [30]	AMI, (4-7 days post MI) IC	↑LVEF (4.6%), ↓LVESV, ↓CE, ↓rest/UA	7 660	3-18
Brunskill et al. 2009 [31]	AMI/IHD, IM/IC	IM delivery > IC delivery ↑LVEF (5.9%)	21 1091	3-6
Jeevanantham et al. 2012 [32]	AMI/IHD, IM/IC	↑LVEF (4.0%), ↓ scar size (-4.0%) ↓LVESV (-8.9 mL), ↓LVEDV (-5.2 mL)	50 2625	variable
Delewi et al. http://onlinelibrary.wiley.com/doi/10.1002/clc.22381/full - clc22381-bib-00532013 [33]	AMI, IC	↑LVEF (3.9%), ↓scar size NS, ↓LVESV (-9.4 mL), ↓recur AMI ↓rehosp HF, UA	26 1710	6-12
Fisher et al. 2014 [34]	IHD/HF, IC	Mortality ↓, ↑LVEF (2.6%)	23 1255	variable
Tian et al. 2014 [35]	IHD IM	↑LVEF (4.9%), ↓LVESV (-10.7 mL)	11 492	6-12
Gyöngyösi et al. 2015 [36]	AMI (based on individual patient data, at different time post AMI (e.g.: from 24 hours to 3 months after AMI).	no impact on LV remodeling, or myocardial contraction, no significant effect on clinical outcomes in AMI	12 1252	6